GnP is named as a drug or biological intervention in 2 clinical trials in our USA trial register, 2 of which are recruiting. Lead sponsors include Immuneering Corporation (1) and Alterome Therapeutics, Inc. (1). Registered phases: Phase 3 and Phase 1. Conditions studied include PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Pancreatic Cancer Metastatic.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07562152 | Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (ClinicalTrials.gov ↗) Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC |
Phase 3 | Recruiting |
| NCT06835569 | A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations (ClinicalTrials.gov ↗) Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer) |
Phase 1 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| PDAC - Pancreatic Ductal Adenocarcinoma | 2 |
| Pancreatic Cancer | 1 |
| Pancreatic Cancer Metastatic | 1 |
| PDAC | 1 |
| Cancer | 1 |
| NSCLC (Non-small Cell Lung Cancer) | 1 |
| CRC (Colorectal Cancer) | 1 |
| Lead sponsor | Trials |
|---|---|
| Immuneering Corporation | 1 |
| Alterome Therapeutics, Inc. | 1 |
| Register | GnP trials |
|---|---|
| Clinical trials in USA | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how GnP works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists GnP (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.